These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 28455745

  • 21. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 22. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
    Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):643-650. PubMed ID: 32241780
    [Abstract] [Full Text] [Related]

  • 23. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
    Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE.
    J Am Soc Nephrol; 2018 Oct 07; 29(10):2458-2470. PubMed ID: 30228150
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
    Torres VE.
    Nephrol Dial Transplant; 2019 Jan 01; 34(1):30-34. PubMed ID: 30312438
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT, Torres VE.
    Am J Kidney Dis; 2021 Aug 01; 78(2):282-292. PubMed ID: 33705818
    [Abstract] [Full Text] [Related]

  • 31. The cellular pathways and potential therapeutics of Polycystic Kidney Disease.
    Richards T, Modarage K, Malik SA, Goggolidou P.
    Biochem Soc Trans; 2021 Jun 30; 49(3):1171-1188. PubMed ID: 34156429
    [Abstract] [Full Text] [Related]

  • 32. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Aug 15; 18(1):268. PubMed ID: 28810844
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
    Kramers BJ, Koorevaar IW, van Gastel MDA, van Goor H, Hallows KR, Heerspink HL, Li H, Leonhard WN, Peters DJM, Qiu J, Touw DJ, Gansevoort RT, Meijer E.
    Clin J Am Soc Nephrol; 2022 Apr 15; 17(4):507-517. PubMed ID: 35314480
    [Abstract] [Full Text] [Related]

  • 35. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.
    Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W.
    Nephrol Dial Transplant; 2016 Mar 15; 31(3):337-48. PubMed ID: 26908832
    [Abstract] [Full Text] [Related]

  • 36. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K, Kitayama C, Yanai A, Ishibashi Y.
    Sci Rep; 2021 Sep 03; 11(1):17666. PubMed ID: 34480075
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W.
    Clin Exp Nephrol; 2021 Nov 03; 25(11):1231-1239. PubMed ID: 34228250
    [Abstract] [Full Text] [Related]

  • 39. Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment.
    Minatoguchi S, Hayashi H, Umeda R, Koide S, Hasegawa M, Tsuboi N.
    CEN Case Rep; 2024 Oct 03; 13(5):419-424. PubMed ID: 38494546
    [Abstract] [Full Text] [Related]

  • 40. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.
    Kidney Int; 2011 Aug 03; 80(3):295-301. PubMed ID: 21544064
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.